Additional Relevant Details A poster presentation and discussion by investigators from the Icahn School of Medicine at Mount Sinai in New York evaluated the activity and molecular effects of the rigosertib/azacitidine combination in myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML) cell lines and patients' bone marrow. The studies confirmed synergistic activity, while also revealing a novel effect on epigenetics. Onconova is currently evaluating the combination of oral rigosertib and azacitidine in a fully enrolled, multi-center Phase 2 trial (NCT01926587). An update on this study will be presented at the European Hematology Association meeting to be held later this month.